Doxorubicin
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Doxolipad | — | 2019-08-08 | europa.eu ↗ |
| Label expansions (6) | US (FDA) | DOXIL (LIPOSOMAL) | — | 1999-06-28 – 2015-04-16 | fda.gov ↗ |
| Label expansion | US (FDA) | DOXORUBICIN HYDROCHLORIDE | — | 2003-05-08 | fda.gov ↗ |
| Approved | EU (EMA) | Caelyx pegylated liposomal | — | 1996-06-20 | europa.eu ↗ |
| Approved | US (FDA) | DOXORUBICIN HYDROCHLORIDE | — | 1974-08-07 | fda.gov ↗ |
Trials 1,187 · started per year
Press releases naming this drug 158 releases
Evidence & citations 72 cited values
Every value below carries the sentence it was read from. 2,206 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | doxorubicin | “Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane...” NCT05415215 ↗1853“including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗ “Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone,...” NCT00577096 ↗ “Patients initially received one 21-day cycle of standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP; rituximab 375 mg/m2, cyclophosphamide...” PMID 30948276 ↗ Apr 2019 “All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone)...” NCT05874778 ↗ “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗ “The liquid chemotherapeutic drugs (Cisplatin 10.5 mg/m2 body surface in a total of 150 mL NaCl 0.9 %; Doxorubicin 2.1 mg/m2 body surface in a total of 50 mL NaCl 0.9 %) are...” NCT05303714 ↗ “The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1...” NCT04842318 ↗ “standard CHOP chemotherapy (cyclophosphamide, 750mg per square meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area, maximal dose is 2mg d1,...” NCT02487316 ↗ “Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗ “This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients...” NCT04546620 ↗ |
| Known as | ADM | “AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W” NCT04699214 ↗3“Clinical research results show that doxorubicin (ADM) is the basic and standard drug for the treatment of soft tissue sarcoma” NCT06849986 ↗ “High grade LPS: ADM (doxorubicin) 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m3 Q3 weeks.” NCT04031677 ↗ “Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) ]± Rituximab (R)” NCT06520163 ↗ |
| Known as | Adriamycin | “To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; Adcetris) in the chemotherapy backbone of doxorubicin hydrochloride...” NCT02166463 ↗137“The Pediatric Hodgkin Consortium hypothesized that by increasing chemotherapeutic dose density for Hodgkin lymphoma (HL) they could increase the complete response (CR) rate...” PMID 41529162 ↗ Mar 2026 “Patients will be randomized to receive 5 cycles of combination chemotherapy (5-FU, adriamycin, leucovorin, cytoxan, G-CSF) either as initial therapy (preoperative) or...” NCT00001250 ↗ “The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone,...” NCT00107614 ↗ “OBJECTIVE: To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone (VAMP) in patients with favorable-risk Hodgkin lymphoma...” PMID 22735430 ↗ Jun 2012 “In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0...” NCT00206518 ↗ “R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by...” NCT01852435 ↗ “Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients...” NCT00471965 ↗ “Study on the Treatment of Double/Triple-hit Diffuse Large B-cell Lymphoma With Chidamide and Lisaftoclax in Combination With Vepesidil, Rituximab, Cyclophosphamide, Adriamycin,...” NCT07552324 ↗ “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery” NCT02620280 ↗ |
| Known as | Adriamycin (doxorubicin) | “Adriamycin® (doxorubicin)” NCT00365365 ↗1“Adriamycin (Doxorubicin)” NCT00636441 ↗ |
| Known as | Adriamycin(R) Doxorubicin | “Adriamycin(R) Doxorubicin” NCT00991211 ↗ |
| Known as | Adriamycine | “CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg...” NCT02042391 ↗4“VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20.” NCT00461747 ↗ “Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.” NCT00590447 ↗ “VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1” NCT00560053 ↗ |
| Known as | Adriblastin | “Doxorubicin 60mg/m2(Adriblastin)” NCT06531447 ↗ |
| Known as | Caelyx | “Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or...” NCT00030784 ↗18“giving docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and trastuzumab before surgery in treating women with operable or locally advanced...” NCT00434031 ↗ “Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or...” NCT00652041 ↗ “Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.” NCT00103506 ↗ “Liposomal Doxorubicin (CaelyxTM) could be an adequate replacement of doxorubicin to avoid potential side effects such as cardiotoxicity, alopecia, GI toxicity.” NCT01148628 ↗ “pegylated liposomal doxorubicin (Caelyx®) in combination with biological treatment panitumumab (Vectibix®).” NCT00861120 ↗ “Pegylated Liposomal Doxorubicin (Caelyx) has been developed to reduce the risk of cardiotoxicity.” NCT00780039 ↗ “Caelyx is a chlorhydrate of doxorubicin encapsulated within a pegylated liposome.” NCT06356883 ↗ “pegylated liposomal doxorubicin (Doxil/Caelyx), referred to as the DBd regimen” NCT00570180 ↗ “DOXIL®/ Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks” NCT01204996 ↗ “Interest of the use of pegylated liposomal doxorubicin (caélyx)” NCT00536393 ↗ |
| Known as | CaelyxTM | “Liposomal Doxorubicin (CaelyxTM) could be an adequate replacement of doxorubicin to avoid potential side effects such as cardiotoxicity, alopecia, GI toxicity.” NCT01148628 ↗ |
| Known as | D-MNA | “D-MNA, (doxorubicin) patch, 200µg” NCT06608238 ↗ |
| Known as | DLI | “doxorubicin HCl liposome injection (DLI)” PMID 24285015 ↗ Nov 2013 |
| Known as | DOX | “PURPOSE: Here we report a phase II clinical trial, which was designed to test a novel hypothesis that treatment with gemcitabine (GEM)/doxorubicin (DOX) would be efficacious...” PMID 21791630 ↗ Jul 201124“Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗ “Previous phase I/II trials indicate promising activity of lurbinectedin plus doxorubicin (DOX) in leiomyosarcoma (LMS).” PMID 39932221 ↗ Feb 2025 “MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs).” NCT00041808 ↗ “MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs).” NCT00034333 ↗ “MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick," to magnetic beads (MTCs).” NCT00054951 ↗ “Arm II: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002493 ↗ “methotrexate (MTX) intrathecally (IT), doxorubicin (DOX) IV, and hydrocortisone (HC) IT on day 1” NCT00006455 ↗ “Doxorubicin (DOX), a prominent anthracycline, is used to treat malignancies” PMID 41034674 ↗ Oct 2025 “loaded with 33mg/ml doxorubicin (Dox) and 0.3mg/mL nicardipine (Nic)” NCT07302919 ↗ “PK profiles of doxorubicin (DOX) and doxorubicinol (DOXOL)” PMID 33063185 ↗ Oct 2020 |
| Known as | DOX-SL | “To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with...” NCT00002105 ↗2“To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of...” NCT00001059 ↗ “Stealth liposomal doxorubicin hydrochloride ( DOX-SL )” NCT00002147 ↗ |
| Known as | Doxil | “The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug combination of Doxil (doxorubicin) and estramustine when used to treat...” NCT00132756 ↗55“Patients will be stratified by 4 criteria defined in the protocol and randomly assigned in a 1:1 ratio to the trabectedin+DOXIL combination therapy group (Arm A) or to the...” NCT01846611 ↗ “OBJECTIVES: I. Determine the maximum tolerated dose of doxorubicin HCl liposome (Doxil) when combined with carboplatin in patients with recurrent ovarian, fallopian tube, or...” NCT00006235 ↗ “Doxil is a doxorubicin formulation in which the drug is encapsulated in liposomes (Stealthâ liposomes) that escape instant recognition and uptake by the mononuclear phagocyte system.” NCT00248248 ↗ “Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.” NCT00103506 ↗ “Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)” NCT03964090 ↗ “DOXIL pegylated liposomal doxorubicin (PLD) is approved for use in patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.” NCT00698451 ↗ “Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)” NCT02203526 ↗ “This liposomally encapsulated form of doxorubicin called Doxil has shown similar or better anti-tumor against certain tumors with reduced side effects.” NCT00184002 ↗ “Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.” PMID 15721421 ↗ Mar 2005 “A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma” NCT00003388 ↗ |
| Known as | Doxorubicin (A) | “Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5” NCT00774826 ↗ |
| Known as | Doxorubicin (Adriamycin) | “Doxorubicin (Adriamycin®)” NCT02128230 ↗1“Doxorubicin (Adriamycin)” NCT00878800 ↗ |
| Known as | Doxorubicin (Adryamicin) | “Doxorubicin (Adryamicin)” NCT01527422 ↗ |
| Known as | Doxorubicin brand name Adriamycin. | “Doxorubicin brand name Adriamycin.” NCT00949182 ↗ |
| Known as | doxorubicin HCl | “doxorubicin HCl liposome injection” NCT00057720 ↗ |
| Known as | doxorubicin HCl liposomal | “Determine the optimal dose of doxorubicin HCl liposomal and prolonged oral etoposide” NCT00003380 ↗ |
| Known as | doxorubicin HCl liposomal injection | “DOXIL (doxorubicin HCl liposomal injection)” NCT00344422 ↗ |
| Known as | doxorubicin HCl liposome | “Determine the tolerance to and toxicity profile of doxorubicin HCl liposome (Lipodox) at standard doxorubicin doses and doses of Lipodox that were tolerable in adults...” NCT00019630 ↗11“OBJECTIVES: I. Determine the maximum tolerated dose of doxorubicin HCl liposome (Doxil) when combined with carboplatin in patients with recurrent ovarian, fallopian tube, or...” NCT00006235 ↗ “Patients receive doxorubicin HCl liposome IV over 1 hour on day 1 and ifosfamide IV over 4 hours on days 1-3 OR on days 1-4 (for patients enrolled on dose level 6).” NCT00030784 ↗ “Patients receive doxorubicin HCl liposome IV over 1 hour followed 30 minutes later by trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15.” NCT00004925 ↗ “OBJECTIVES: I. Determine the response rate and toxicity of doxorubicin HCl liposome in patients with carcinomas of the liver and bile ducts.” NCT00003296 ↗ “Determine the maximum tolerated dose of doxorubicin HCl liposome when administered with carboplatin in patients with gynecological tumors.” NCT00032162 ↗ “Patients receive doxorubicin HCl liposome IV over 1 hour on day 1, followed by oral etoposide for 8-14 days beginning on day 2.” NCT00003380 ↗ “All patients receive a 30 minute infusion of doxorubicin HCl liposome IV, cyclophosphamide IV, and vincristine IV on day 1” NCT00003388 ↗ “Patients are randomly assigned to receive doxorubicin HCl liposome (Doxil) or daunorubicin (DaunoXome) in a 3:1 ratio.” NCT00002985 ↗ “Patients receive doxorubicin HCl liposome IV over 60 minutes followed by ZD0473 IV over 60 minutes on day 1.” NCT00016172 ↗ “doxorubicin HCl liposome (LipoDox) IV over 30 minutes once every 3 weeks” NCT00020449 ↗ |
| Known as | doxorubicin HCl liposome injection | “A Phase II Study to Assess the Safety and Efficacy of DBd Combination Therapy (DOXIL/CAELYX) [Doxorubicin HCL Liposome Injection], VELCADE [Bortezomib] and Dexamethasone) for...” NCT00561743 ↗4“DOXIL (doxorubicin HCl liposome injection)” NCT00097981 ↗ “DOXIL (Doxorubicin HCL Liposome Injection)” NCT00442260 ↗ “doxorubicin HCl liposome injection (DLI)” PMID 24285015 ↗ Nov 2013 “Doxorubicin HCL liposome injection” NCT01593228 ↗ |
| Known as | doxorubicin hydrochloride | “Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing...” NCT01476410 ↗228“This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3...” NCT00041119 ↗ “Pegylated liposomal doxorubicin (PLD), which contains a cytotoxic drug called doxorubicin hydrochloride, is one of several treatment modalities that may be considered for...” PMID 37407274 ↗ Jul 2023 “Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.” NCT00103506 ↗ “Patients with localized progression or threatening symptoms undergo N4 chemotherapy comprising doxorubicin hydrochloride IV over 30 minutes and vincristine IV on days 1, 3, and 5” NCT00410631 ↗ “Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells” NCT00896519 ↗ “Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.” NCT05481645 ↗ “neoadjuvant dose-dense chemotherapy comprising doxorubicin hydrochloride, ifosfamide, and irinotecan hydrochloride in combination with dexrazoxane hydrochloride” NCT00544778 ↗ “Patients receive doxorubicin hydrochloride IV over 1 hour followed by carboplatin intraperitoneally on day 1 until the maximum tolerated dose is achieved.” NCT00562185 ↗ “dose-dense AC-T regimen comprising doxorubicin hydrochloride intravenously (IV) and cyclophosphamide IV once every 2 weeks for 4 courses” NCT01147016 ↗ “fluorouracil, doxorubicin hydrochloride, and cyclophosphamide followed by trastuzumab (Herceptin®) and paclitaxel.” NCT00533936 ↗ |
| Known as | doxorubicin hydrochloride iposome | “doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)” NCT02577783 ↗ |
| Known as | Doxorubicin Hydrochloride Liposome | “Doxorubicin Hydrochloride Liposome: 25 mg/m² , intravenous drip, Day 2 of each cycle” NCT07499271 ↗ |
| Known as | doxorubicin hydrochloride liposome injection | “Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose).” NCT03681548 ↗1“doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1” NCT02631109 ↗ |
| Known as | Doxorubicin Transdrug (DT) | “Doxorubicin Transdrug (DT) at 20 mg/m2” NCT01655693 ↗ |
| Known as | doxorubicine | “Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine,...” NCT00554164 ↗14“Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)” NCT04307277 ↗ “Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma” NCT02997358 ↗ “doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator” NCT02684708 ↗ “GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine.” NCT03346642 ↗ “R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone)” NCT02858258 ↗ “Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1°” NCT00795613 ↗ “cisplatin, vindesine, ifosfamide, dacarbacine, doxorubicine” NCT03042429 ↗ “doxorubicine (DOX) on days 8, 15, 22 and 29 (4 doses)” NCT01117441 ↗ “Doxorubicine, IV, D1-D2, 37.5mg/m²” NCT03011528 ↗ “Doxorubicine 50 mg/m2 D1, I.V.” NCT06255704 ↗ |
| Known as | Doxorubicine pegylated | “Doxorubicine pegylated 40 MG/M² J1 2 courses” NCT00600977 ↗ |
| Known as | Doxorubin HCI, Pegylated Liposomal | “Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or...” NCT00030784 ↗ |
| Known as | duomeisu | “this study aims to observe and explore the efficacy and safety of the combination of albumin-bound paclitaxel (keaili) and liposomal doxorubicin (duomeisu) in the treatment of...” NCT04859465 ↗1“doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)” NCT02577783 ↗ |
| Known as | duoroubixing | “doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)” NCT02577783 ↗ |
| Known as | DXR | “oxaliplatin (OXA) 120 mg/sm, cisplatin (CDDP) 10.5 mg/sm and doxorubicin (DXR) 2.1 mg/sm.” PMID 34070561 ↗ May 2021 |
| Known as | hydroxydaunomycin | “The drugs in this combination are "R" for rituximab, "C" for cyclophosphamide, "H" for doxorubicin which has a chemical name of hydroxydaunomycin, "O" for vincristine which has...” NCT02285062 ↗ |
| Known as | hydroxydaunorubicin | “CHOP chemotherapy is made up of the drugs cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone.” NCT01321008 ↗11“CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)” NCT06006117 ↗ “CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)” NCT06947967 ↗ “CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)” NCT00719472 ↗ “Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone” NCT06072131 ↗ “CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone” NCT00974324 ↗ “doxorubicin hydrochloride (hydroxydaunorubicin)(EPOCH)” NCT00001337 ↗ “Hydroxydaunorubicin: 50 mg/m2 i.v. day1” NCT00791947 ↗ |
| Known as | Hydroxyldaunorubicin | “Hydroxyldaunorubicin (Doxorubicin)®” PMID 33394214 ↗ Jan 2021 |
| Known as | LED | “Liposome-Encapsulated Doxorubicin (LED) in Hormone Refractory Prostate Carcinoma, Phase II” NCT00004014 ↗ |
| Known as | LipoDox | “Determine the tolerance to and toxicity profile of doxorubicin HCl liposome (Lipodox) at standard doxorubicin doses and doses of Lipodox that were tolerable in adults...” NCT00019630 ↗3“OUTLINE: This is a dose-escalation study of doxorubicin HCl liposome (LipoDox).” NCT00003385 ↗ “doxorubicin HCl liposome (LipoDox) IV over 30 minutes once every 3 weeks” NCT00020449 ↗ “PLD (Lipo-Dox®, Liposomal Doxorubicin Injection)” NCT07565324 ↗ |
| Known as | liposomal doxorubicin | “BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This...” PMID 25025963 ↗ Jul 201448“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Liposomal Doxorubicin; * Docetaxel; *...” NCT03949283 ↗ “this study aims to observe and explore the efficacy and safety of the combination of albumin-bound paclitaxel (keaili) and liposomal doxorubicin (duomeisu) in the treatment of...” NCT04859465 ↗ “giving docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and trastuzumab before surgery in treating women with operable or locally advanced...” NCT00434031 ↗ “Phase I trial to study the effectiveness of combining liposomal doxorubicin with ifosfamide in treating patients who have advanced or metastatic soft tissue sarcoma.” NCT00030784 ↗ “Liposomal Doxorubicin (CaelyxTM) could be an adequate replacement of doxorubicin to avoid potential side effects such as cardiotoxicity, alopecia, GI toxicity.” NCT01148628 ↗ “treatment regimens containing either bortezomib, liposomal doxorubicin and dexamethasone (VDD), or lenalidomide, bortezomib and dexamethasone (RVD).” PMID 25824111 ↗ Mar 2015 “Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks.” NCT06977893 ↗ “A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma” NCT00003388 ↗ “Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of phosphatidylcholine and cholesterol.” NCT00886028 ↗ “PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver or bile duct cancer.” NCT00003296 ↗ |
| Known as | liposomal doxorubicin hydrochloride | “To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of...” NCT00001059 ↗ |
| Known as | Liposome-Encapsulated Doxorubicin | “Liposome-Encapsulated Doxorubicin (LED) in Hormone Refractory Prostate Carcinoma, Phase II” NCT00004014 ↗ |
| Known as | low temperature liposomal doxorubicin | “Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local...” PMID 25144817 ↗ Aug 2014 |
| Known as | LTLD | “Lyso-thermosensitive liposomal doxorubicin (LTLD) is a temperature sensitive liposome which is systemically administered and is engineered to selectively release its...” NCT02850419 ↗2“Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local...” PMID 25144817 ↗ Aug 2014 “Lyso-Thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox, Celsion Corporation, Lawrenceville, NJ, USA)” PMID 33243800 ↗ Nov 2020 |
| Known as | LY01612 | “A multicenter, randomized, open-lable, single-dose, two-cycle, double-cross bioequivalence study comparing the pharmacokinetic profile of LY01612 (Doxorubicin hydrochloride...” NCT06098599 ↗ |
| Known as | Lyso-thermosensitive liposomal doxorubicin | “Lyso-thermosensitive liposomal doxorubicin (LTLD) is a temperature sensitive liposome which is systemically administered and is engineered to selectively release its...” NCT02850419 ↗4“Lyso-thermosensitive liposomal doxorubicin (ThermoDox®) is a temperature sensitive liposomal drug delivery system that selectively accumulates in tumors as a result of their...” NCT00826085 ↗ “A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors” NCT02536183 ↗ “lyso-thermosensitive liposomal doxorubicin(Thermodox)” NCT00346229 ↗ “Lyso-thermosensitive Liposomal Doxorubicin” NCT02181075 ↗ |
| Known as | MTC-DOX | “MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs).” NCT00041808 ↗1“MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick," to magnetic beads (MTCs).” NCT00054951 ↗ |
| Known as | Myocet | “the non-pegylated liposomal encapsulated doxorubicin (NPLD) Myocet® might provide the possibility to combine taxane, anthracycline, platinum salt as well with targeted agents...” NCT01426880 ↗13“Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer” NCT00250874 ↗ “Myocet® (non-pegylated liposomal doxorubicin) is one of the several strategies developed to reduce cardiotoxicity” NCT02012088 ↗ “Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy” NCT01100372 ↗ “Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.” NCT00244127 ↗ “iii) 4 cycles of MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)” NCT01564056 ↗ “Myocet (Non-pegylated liposomal doxorubicin (NPLD))” NCT01172223 ↗ “Doxorubicin Liposomal (Myocet ®)” NCT01009970 ↗ |
| Known as | Myocet (liposome-encapsulated doxorubicin) | “Myocet® (liposome-encapsulated doxorubicin)” NCT01669239 ↗ |
| Known as | MyocetTM | “Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy” PMID 20007997 ↗ Dec 2009 |
| Known as | non-pegylated liposomal doxorubicin | “Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)” NCT01619111 ↗ |
| Known as | Non-pegylated liposomal doxorubicin (Myocet): | “Non-pegylated liposomal doxorubicin (Myocet®):” NCT01935492 ↗ |
| Known as | Non-pegylated liposomal doxorubicin (NPLD) | “Myocet (Non-pegylated liposomal doxorubicin (NPLD))” NCT01172223 ↗ |
| Known as | NPLD | “Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)” NCT01619111 ↗ |
| Known as | NSC-123127 | “Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗11“CAF: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Fluorouracil, 5-FU, NSC-19893; followed by TMX.” NCT00929591 ↗ “Arm II: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002493 ↗ “Doxorubicin, DOX, NSC-123127; Estramustine, EM, NSC-89199.” NCT00002721 ↗ “Doxorubicin, DOX, NSC-123127;” NCT00002495 ↗ “Doxorubicin, DOX, NSC-123127;” NCT00001300 ↗ “Doxorubicin, DOX, NSC-123127” NCT00002462 ↗ “DOX Doxorubicin, NSC-123127” NCT00002557 ↗ “DOX Doxorubicin, NSC-123127” NCT00002599 ↗ “DOX Doxorubicin, NSC-123127” NCT00002576 ↗ “DOX Doxorubicin, NSC-123127” NCT00001339 ↗ |
| Known as | PDL | “Patients receive pegylated doxorubicin hydrochloride liposome (PDL) IV over 1 hour on day 1.” NCT00296010 ↗ |
| Known as | pegylated doxorubicin HCl liposome | “Compare overall survival of patients with platinum-sensitive recurrent ovarian epithelial or primary peritoneal cancer treated with carboplatin with or without pegylated...” NCT00043082 ↗ |
| Known as | pegylated liposomal doxorubicin | “Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or...” PMID 17949799 ↗ Oct 200714“Patients will be stratified by 4 criteria defined in the protocol and randomly assigned in a 1:1 ratio to the trabectedin+DOXIL combination therapy group (Arm A) or to the...” NCT01846611 ↗ “A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in...” PMID 17910981 ↗ Oct 2007 “Brecan study evaluated the efficacy and safety of neoadjuvant pegylated liposomal doxorubicin (PLD)/cyclophosphamide and sequential nab-paclitaxel based on HP (PLD/C/HP-nabP/HP).” PMID 37279780 ↗ Jan 2024 “pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS).” PMID 36239473 ↗ Dec 2022 “Caelyx (pegylated liposomal doxorubicin) was designed to reduce the cardiotoxicity of doxorubicin while preserving its antitumor efficacy” NCT00431795 ↗ “previously reported efficacy of pegylated liposomal doxorubicin (PLD) on treatment of early and established mammary tumors.” PMID 22030751 ↗ Oct 2011 “Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.” PMID 17846226 ↗ Sep 2007 “tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy.” PMID 21844495 ↗ Aug 2011 “Phase I Trial of Combination Pegylated Liposomal Doxorubicin (Doxil), Vinorelbine, and Gemcitabine” NCT00006372 ↗ “Pegylated Liposomal Doxorubicin (Caelyx) has been developed to reduce the risk of cardiotoxicity.” NCT00780039 ↗ |
| Known as | Pegylated liposomal doxorubicin (PLD) | “Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis.” NCT04244552 ↗1“Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM).” PMID 30952640 ↗ Apr 2019 |
| Known as | pegylated liposomal doxorubicin hydrochloride | “Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.” NCT00290732 ↗3“pegylated liposomal doxorubicin (pegylated liposomal doxorubicin hydrochloride)” NCT00337194 ↗ “low-dose pegylated liposomal doxorubicin hydrochloride (liposomal doxorubicin)” NCT05711615 ↗ “pegylated liposomal doxorubicin hydrochloride” NCT00020449 ↗ |
| Known as | pegylated liposomal doxorubicin hydrochloride (Doxil) | “pegylated liposomal doxorubicin hydrochloride (Doxil)” NCT00653328 ↗ |
| Known as | PL-doxorubicin | “pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rituximab regimen” NCT03022123 ↗ |
| Known as | PLD | “BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This...” PMID 25025963 ↗ Jul 201411“Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or...” PMID 17949799 ↗ Oct 2007 “A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in...” PMID 17910981 ↗ Oct 2007 “Brecan study evaluated the efficacy and safety of neoadjuvant pegylated liposomal doxorubicin (PLD)/cyclophosphamide and sequential nab-paclitaxel based on HP (PLD/C/HP-nabP/HP).” PMID 37279780 ↗ Jan 2024 “DOXIL pegylated liposomal doxorubicin (PLD) is approved for use in patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.” NCT00698451 ↗ “pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS).” PMID 36239473 ↗ Dec 2022 “Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM).” PMID 30952640 ↗ Apr 2019 “previously reported efficacy of pegylated liposomal doxorubicin (PLD) on treatment of early and established mammary tumors.” PMID 22030751 ↗ Oct 2011 “tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy.” PMID 21844495 ↗ Aug 2011 “pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week)” PMID 32620163 ↗ Jul 2020 “Pegylated liposomal Doxorubicin (PLD)” NCT07218809 ↗ |
| Known as | Rubex (Doxorubicin) | “Rubex (Doxorubicin)” NCT00636441 ↗ |
| Known as | SCH 200746 | “Caelyx (pegylated liposomal doxorubicin; SCH 200746)” NCT00604968 ↗ |
| Known as | Stealth liposomal doxorubicin hydrochloride | “Stealth liposomal doxorubicin hydrochloride ( DOX-SL )” NCT00002147 ↗ |
| Known as | Thermally Sensitive Liposomal Doxorubicin | “ThermoDox (Thermally Sensitive Liposomal Doxorubicin)” NCT02850419 ↗ |
| Known as | ThermoDox | “The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular...” NCT02112656 ↗4“The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular...” NCT00617981 ↗ “OBJECTIVES: * Determine the maximum tolerated dose of temperature-sensitive liposomal doxorubicin (ThermoDox™) when used in combination with local-regional hyperthermia in...” NCT00346229 ↗ “Lyso-thermosensitive liposomal doxorubicin (ThermoDox®) is a temperature sensitive liposomal drug delivery system that selectively accumulates in tumors as a result of their...” NCT00826085 ↗ “ThermoDox (Thermally Sensitive Liposomal Doxorubicin)” NCT02850419 ↗ |
| Known as | TLC D-99 | “A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma” NCT00289809 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.” NCT00002608 ↗ |
| Modality | Other / unclassified | “a thermally sensitive, intravenously administered liposomal formulation of doxorubicin” NCT00441376 ↗ |
| Route | Intravenous | “Four medicines are given on day 1 of each cycle by vein (IV) (doxorubicin, cyclophosphamide, bleomycin, vincristine).” NCT00000689 ↗ |